Skip to content

Study · Animal study (in vivo) · rat · 2017

8 results

Effect of Melanotan-II on Brain Fos Immunoreactivity and Oxytocin Neuronal Activity and Secretion in Rats.

Paiva L, Sabatier N, Leng G, Ludwig M

Journal of neuroendocrinology1 Feb 2017Cited by 9 (Europe PMC)

PMID28009464 (opens in a new tab)DOI10.1111/jne.12454 (opens in a new tab)PepBankPUB-28009464
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats, intravenous MT-II markedly induced Fos expression in magnocellular neurones of the supraoptic and paraventricular nuclei.

    In plain wordsIn rats, MT-II given into a vein switched on a marker of activity in oxytocin-related brain cells.

    Peptide
    Melanotan II
    Outcome
    IncreaseFos expression in SON and PVN after intravenous MT-II
    Study

    ratn: not reported in source

    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    i.v., but not intranasal, administration of MT-II markedly induced Fos expression in magnocellular neurones of the supraoptic (SON) and paraventricular nuclei (PVN) of the hypothalamus
    1 context sentence
    Summary · context
    In the present study, we investigated how systemic administration of melanotan-II (MT-II), a melanocortin agonist, affects oxytocin neuronal activity and secretion in rats.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats, intranasal MT-II did not induce Fos expression in magnocellular neurones of the supraoptic and paraventricular nuclei.

    In plain wordsIn rats, MT-II given through the nose did not switch on the activity marker in these brain cells.

    Peptide
    Melanotan II
    Outcome
    No significant changeFos expression after intranasal MT-II
    Study

    ratn: not reported in source

    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (rat).

    Source sentences

    Summary
    i.v., but not intranasal, administration of MT-II markedly induced Fos expression in magnocellular neurones of the supraoptic (SON) and paraventricular nuclei (PVN) of the hypothalamus
    1 context sentence
    Summary · context
    In the present study, we investigated how systemic administration of melanotan-II (MT-II), a melanocortin agonist, affects oxytocin neuronal activity and secretion in rats.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, the Fos response to intravenous MT-II was attenuated by prior i.c.v. administration of the melanocortin antagonist SHU-9119.

    In plain wordsIn rats, blocking melanocortin receptors in the brain first reduced the activity marker caused by MT-II.

    Peptide
    Melanotan II
    Outcome
    Not applicableMT-II Fos response with SHU-9119 pretreatment
    Study

    ratn: not reported in source

    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    and this response was attenuated by prior i.c.v. administration of the melanocortin antagonist, SHU-9119.
    1 context sentence
    Summary · context
    In the present study, we investigated how systemic administration of melanotan-II (MT-II), a melanocortin agonist, affects oxytocin neuronal activity and secretion in rats.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, intravenous MT-II increased the firing rate of oxytocin neurones in the supraoptic nucleus.

    In plain wordsIn rats, MT-II given into a vein made oxytocin-producing brain cells fire more often.

    Peptide
    Melanotan II
    Outcome
    IncreaseFiring rate of SON oxytocin neurones
    Study

    ratn: not reported in source

    identified magnocellular neurones of the SON (electrophysiology)
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    i.v. administration of MT-II increased the firing rate in oxytocin neurones
    1 context sentence
    Summary · context
    In the present study, we investigated how systemic administration of melanotan-II (MT-II), a melanocortin agonist, affects oxytocin neuronal activity and secretion in rats.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats, intravenous MT-II did not trigger somatodendritic oxytocin release within the supraoptic nucleus, as measured by microdialysis.

    In plain wordsIn rats, MT-II given into a vein did not cause oxytocin release inside this brain region.

    Peptide
    Melanotan II
    Outcome
    No significant changeSomatodendritic oxytocin release in the SON
    Study

    ratn: not reported in source

    microdialysis in the SON
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    did not trigger somatodendritic oxytocin release within the SON as measured by microdialysis.
    1 context sentence
    Summary · context
    In the present study, we investigated how systemic administration of melanotan-II (MT-II), a melanocortin agonist, affects oxytocin neuronal activity and secretion in rats.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats, MT-II also increased Fos expression in the caudal brainstem.

    In plain wordsIn rats, MT-II also switched on the activity marker in the lower brainstem.

    Peptide
    Melanotan II
    Outcome
    IncreaseFos expression in the caudal brainstem
    Study

    ratn: not reported in source

    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    from the caudal brainstem, where MT-II also increased Fos expression.
    1 context sentence
    Summary · context
    In the present study, we investigated how systemic administration of melanotan-II (MT-II), a melanocortin agonist, affects oxytocin neuronal activity and secretion in rats.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 07AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, intravenous Melanotan-II increased the firing rate of the body's own oxytocin neurones in the supraoptic nucleus.

    In plain wordsIn rats, a drug given into a vein made the body's own oxytocin nerve cells fire faster.

    Peptide
    Oxytocin
    Outcome
    IncreaseFiring rate of supraoptic nucleus oxytocin neurones after i.v. Melanotan-II
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    increased the firing rate in oxytocin neurones
    1 context sentence
    Summary · context
    In the present study, we investigated how systemic administration of melanotan-II (MT-II), a melanocortin agonist, affects oxytocin neuronal activity and secretion in rats.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 08AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, intravenous Melanotan-II did not trigger release of the body's own oxytocin within the supraoptic nucleus, as measured by microdialysis.

    In plain wordsIn rats, a drug given into a vein did not cause the body's own oxytocin to be released in this brain area.

    Peptide
    Oxytocin
    Outcome
    No significant changeSomatodendritic oxytocin release in the supraoptic nucleus after i.v. Melanotan-II
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    did not trigger somatodendritic oxytocin release within the SON as measured by microdialysis.
    1 context sentence
    Summary · context
    In the present study, we investigated how systemic administration of melanotan-II (MT-II), a melanocortin agonist, affects oxytocin neuronal activity and secretion in rats.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:04 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.